Zynerba Pharmaceuticals

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) has provided program updates for Fragile X syndrome (FXS), autism spectrum disorder (ASD), 22q11.2 deletion syndrome (22q) and developmental and epileptic encephalopathies …

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE Read More

Zynerba Pharmaceuticals

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel in Fragile X Syndrome

DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) announced the initiation of a pivotal, multinational randomized, double-blind, placebo-controlled, multiple-center, efficacy and safety (RECONNECT) Phase 3 trial.

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel in Fragile X Syndrome Read More
Devereux Advanced Behavioral Health

Devereux and CHOP Co-sponsoring Conference on Providing Care for Children With Autism

VILLANOVA, PA — Devereux Advanced Behavioral Health is teaming up with the Children’s Hospital of Philadelphia (CHOP) to co-sponsor a conference on how best to meet the developmental and behavioral healthcare needs of …

Devereux and CHOP Co-sponsoring Conference on Providing Care for Children With Autism Read More

PA Department of Human Services
Devereux students

Devereux SPARC’s HYPE Program Helps Students with Autism Prepare for University Life

WEST CHESTER, PA — The Devereux Advanced Behavioral Health Southeastern Pennsylvania Autism Resource Center (SPARC) and Devereux Pennsylvania Community Adult Autism Partnership Program (CAAPP) recently partnered with West Chester University (WCU) to create a specialized …

Devereux SPARC’s HYPE Program Helps Students with Autism Prepare for University Life Read More

Zynerba Pharmaceuticals

Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel in Children and Adolescents

DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, presented a poster recently at SLEEP 2021, the …

Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel in Children and Adolescents Read More
Zynerba Pharmaceuticals

Zynerba Pharmaceuticals Announces Poster at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting

DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) announced the acceptance and presentation details of a poster at SLEEP 2021, the 35th Annual Meeting of the Associated Professional Sleep Societies, LLC, …

Zynerba Pharmaceuticals Announces Poster at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting Read More